MiniMed Group (MMED) news centers on diabetes technology, insulin delivery systems, CGM integrations, automated insulin delivery algorithms, and the company's development as a newly public Nasdaq-listed medical device business. MiniMed describes itself as a global leader in insulin delivery, with therapies supporting people with diabetes in more than 80 countries.
MMED headlines often matter because the company operates in a regulated care category where product access, sensor compatibility, clinical evidence, reimbursement availability, and regulatory clearances can affect adoption. Company announcements have covered U.S. and European product launches, MiniMed Flex™ availability, Instinct sensors made by Abbott, SmartGuard™ technology, Medicare and Medicare Advantage access, FDA-related activity, CE Mark activity, and pivotal trial updates.
Investors following MiniMed news also watch earnings releases, investor conference participation, board updates, separation-related developments, Medtronic ownership context, and SEC-filed material event reports. Because MiniMed's ecosystem combines pumps, sensors, algorithms, apps, and service, product news can touch several parts of the diabetes management experience at once.
Frequent review of MMED news can help track how MiniMed communicates product availability, regulatory progress, clinical evidence, financial results, and governance changes as an independent public company in diabetes technology.
Medtronic (MDT) launched an exchange offer on September 14, 2026 to divest at least 80.1% of MiniMed Group.
MiniMed, its former Diabetes business now trading as MMED, was IPO’d in March 2026, with Medtronic retaining about 90% (252,813,348 shares). The offer lets Medtronic shareholders swap Medtronic ordinary shares for MiniMed common stock, generally on a tax-free basis for U.S. federal income tax purposes, at a 7% discount, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share.
If the cap does not apply, tendering holders are expected to receive MiniMed shares worth about $107.53 for each $100 of Medtronic stock tendered. Medtronic is offering up to 225,361,295 MiniMed shares, and may exchange an additional 27,452,053 shares if the offer is oversubscribed, fully exiting MiniMed. Completion requires at least 112,680,647 MiniMed shares to be issued in the offer and a favorable tax opinion.
MiniMed (Nasdaq: MMED) reported Q1 FY27 net sales of $843 million, up 16.6% as reported and 15.8% organic, including an estimated 4–6% benefit from an extra week in the 52–53 week fiscal calendar. Excluding this benefit, MiniMed achieved low double-digit organic growth.
International net sales rose to $603 million, up 18.1% reported and 16.9% organic, supported by Simplera capacity expansion and the Instinct sensor. U.S. net sales reached $240 million, up 13.1%, with U.S. New Pumps Sold growing over 20% year over year and worldwide NPS of ~34,000 (+7.7%). The worldwide CGM attachment rate increased to 69%, about 100 bps higher quarter over quarter.
MiniMed advanced its pipeline with a U.S. FDA submission for the MiniMed Fit patch pump, CE Mark for MiniMed Flex with a November EU launch expected, completion of enrollment in the Vivera fully-closed loop U.S. pivotal trial, and IDE approval for a next‑gen extended wear sensor. For FY27, MiniMed now expects organic revenue growth of ~10.5%, including a 1.0–1.5% extra-week benefit, up from ~10%, and reaffirms an adjusted EBITDA margin outlook of ~16%.
MiniMed (Nasdaq: MMED) announced that its management will join fireside chats at two investor conferences. The company will participate in the 21st Annual Wells Fargo Healthcare Conference on September 8, 2026, at 3:00 p.m. EDT / 12:00 p.m. PDT, featuring CEO Que Dallara. MiniMed will also attend the Bank of America Global Healthcare Conference 2026 on September 23, 2026, at 10:55 a.m. BST / 5:55 a.m. EDT / 2:55 a.m. PDT with CEO Que Dallara and CFO Chad Spooner. According to MiniMed, live webcasts and replays will be available on its investor relations website.
MiniMed (Nasdaq: MMED) announced that its MiniMed Flex™ automated insulin delivery system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. For the first time, users can combine MiniMed’s smallest and only app-controlled insulin pump with what the company calls the world’s smallest, patient-applied sensor, offering up to 15 days of wear.
Powered by SmartGuard™ technology, MiniMed Flex™ automatically adjusts insulin around the clock and uses Meal Detection™ to help when meal boluses are occasionally missed. The pump holds up to 300 units of insulin, works with the Extended™ infusion set for up to seven days’ wear, and is FDA cleared for people with type 1 diabetes aged 7+ and adults with insulin-requiring type 2 diabetes.
MiniMed (Nasdaq: MMED) announced that Medicare and Medicare Advantage beneficiaries in the U.S. now have access to the MiniMed Flex™ insulin pump system with its latest sensor portfolio. This expansion makes MiniMed’s smallest and only app-controlled pump available to more people living with diabetes.
MiniMed Flex™ is about half the size of previous MiniMed pumps, roughly the size of two stacked insulin vials, yet holds 300 units of insulin. Powered by the same SmartGuard™ technology used in the MiniMed™ 780G system, it automatically adjusts insulin delivery every five minutes. According to MiniMed, real-world data in Medicare users of MiniMed™ 780G showed glycemic outcomes exceeding American Diabetes Association targets. In the U.S., MiniMed Flex™ is available with the Simplera Sync™ sensor and is expected to be available with Abbott’s Instinct sensor later this summer.
MiniMed (Nasdaq: MMED) announced it expects to report fiscal year 2027 first quarter financial results on Tuesday, September 1, 2026, covering the quarter ended July 31, 2026. A summary news release is expected around 3:45 a.m. PDT, followed by a webcast from 5:45 to 6:30 a.m. PDT, with replay and transcript available within 24 hours on the company’s investor website.
MiniMed (Nasdaq: MMED) appointed Alcon CEO David Endicott and Medtronic executive Linnea Burman to its Board of Directors, effective June 29, 2026, expanding the board from nine to 11 members.
Endicott joins the Compensation and Talent Committee, while Medtronic remains MiniMed's majority shareholder.
MiniMed (Nasdaq: MMED) launched in Europe the MiniMed™ 780G system integrated with the 15-day Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor, both made by Abbott.
CE-marked Instinct sensors expand MiniMed's portfolio, offering smaller, longer-wear CGM options with clinical data showing high Time in Range and strong overnight control.
MiniMed (Nasdaq: MMED) has commercially launched the MiniMed Flex™ system in the U.S., its first app-controlled and smallest insulin pump, paired initially with the Simplera Sync™ sensor.
The pump holds 300 units, uses the SmartGuard™ algorithm with Meal Detection™ technology, and real‑world data showed about 80% Time in Range with recommended settings. FDA clearance covers type 1 diabetes from age 7 and insulin‑requiring type 2 adults.
MiniMed (NASDAQ: MMED) announced an expanded agreement with Abbott to commercialize integrated dual glucose-ketone sensors designed to work exclusively with MiniMed smart dosing systems.
The same-size-as-Instinct sensors aim to enable early, real-time ketone detection to help prevent diabetic ketoacidosis (DKA). Abbott’s dual systems have CE Mark, are under FDA review, and are not yet cleared or available in the United States.